https://twitter.com/renalandurology/status/1721918778773045568The risks for cardiovascular and renal events do not differ between new febuxostat and allopurinol users who have stage 3 or higher chronic #kidneydiseases (CKD) not on dialysis, investigators reported at #KidneyWk. https://bit.ly/40sCuQ4
— Renal & Urology News (@renalandurology) Nov 7, 2023
Tuesday, November 7, 2023
@renalandurology
http://twitter.com/renalandurology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment